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Abstract
Myotonic dystrophy type 1 (DM1) is a neuro-
muscular disorder caused by a CTG repeat
expansion in 3’UTR of DMPK gene. This muta-
tion causes accumulation of toxic RNA in
nuclear foci leading to splicing misregulation
of specific genes. In view of future clinical tri-
als with antisense oligonucleotides in DM1
patients, it is important to set up sensitive and
minimally-invasive tools to monitor the effica-
cy of treatments on skeletal muscle. A tibialis
anterior  (TA) muscle sample of about 60 mg
was obtained from 5 DM1 patients and 5
healthy subjects through a needle biopsy. A
fragment of about 40 mg was used for histolog-
ical examination and a fragment of about 20
mg was used for biomolecular analysis. The TA
fragments obtained with the minimally-inva-
sive needle biopsy technique is enough to per-
form all the histopathological and biomolecu-
lar evaluations useful to monitor a clinical trial
on DM1 patients.
Introduction
Myotonic dystrophy type 1 (DM1) is the
most common muscular dystrophy in adults,
affecting 1 in 6-10,000 live birth. Main clinical
features of DM1 are myotonia, weakness and
atrophy of skeletal muscles.1 DM1 is caused by
the expansion of a CTG repeat (from 50 to
3000 repeats) in the 3’ untranslated region of
the Dystrophia Myotonica Protein Kinase
(DMPK) gene.2-4 This mutation gives rise to
toxic RNAs containing repetitive CUG repeat
that accumulate in cell nuclei as ribonuclear
inclusions causing changes of alternative
splicing for a specific group of transcripts.5,6
Expanded CUG repeats interact with RNA-
binding proteins such as Muscleblind-like
(MBNL) protein family, causing their nuclear
sequestration and subsequently resulting in
reduced protein activity in several cellular
processes.7-9 Another pathogenic effect of
DMPK mutation is the induction of post-tran-
scriptional upregulation of another RNA bind-
ing protein, CUG-binding protein 1
(CUGBP1).10 MBNLs and CUGBP1 are antago-
nistic regulators of alternative splicing, and
their functional imbalance leads to embryonic
patterns of alternative splicing in adult DM1
tissues.11
Currently, there are no disease-modifying
therapies for patients with DM1 and treat-
ments are only to manage symptoms. To date,
two main experimental therapeutic strategies
of targeting expanded repeat RNA in DM1 have
been described: i) antisense oligomer-induced
degradation of toxic CUG-containing RNA;12-20
and ii) inhibition of pathogenic interaction of
CUG-containing RNA with nuclear proteins
without causing significant degradation of tar-
geted transcript, by either antisense oligomers
(ASOs) or small compounds that bind to CUG
repeat hairpin.21-23 The expected effects of
these treatments are the prevention of MBNLs
sequestration and/or a significant reduction of
nuclear foci formation. These results should
lead to the correction of alternative splicing
abnormalities for several MBNL-sensitive
exons. Indeed, alternative splice events have
good potential to function as biomarkers of DM
severity and therapeutic response since the
splicing misregulation is directly connected to
RNA toxicity and proteins sequestrations.
Moreover, many splicing defects are correlated
with muscle weakness and histopathology and
some of them directly implicated in symptoms
of DM1.24-28 However, at skeletal muscle level,
still there is no a definitive mechanistic expla-
nation for the histopathological features of
this disease.29 Recent studies have indicated
that the distal muscle tibialis anterior (TA) is
the best muscle to be used to test therapeutic
interventions in DM1 patients because it is
preferentially affected at both histological and
functional level. Moreover, in DM1 patients
splicing events are more severely affected in
TA than in proximal muscles such as vastus
lateralis or biceps brachii, indicating that TA
biopsies are suitable for biomarker discovery
in DM1.27,28 It should be noted that serial mus-
cle samplings will be required to test a thera-
peutic response in skeletal muscle, thus the
analysis must be performed on small tissue
samples easily obtained by minimally invasive
biopsy procedures such as needle biopsy tech-
nique. 
Muscle needle biopsy was developed by
Bergström in 1962 as an alternative to open
biopsy.30 Needle biopsy is a less invasive proce-
dure than open biopsy, presents a low compli-
cation rates and the scar is shorter. It is partic-
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ularly indicated for the diagnosis of neuromus-
cular disease in infancy and childhood or in
inflammatory myopathy and to evaluate the
disease progression and the response to treat-
ment. The sample size obtained by this tech-
nique is smaller than that obtained with an
open biopsy and some limitations are the
impossibility to directly visualize the site of
sampling and the difficulty to identify the right
orientation of the fibres of the obtained sam-
ple. However, a recent study on more than
13,000 patients demonstrated that using nee-
dle biopsy it is possible to obtain an appropri-
ate sample for the analyses required in >99%
of cases.31
In this work we show that, taking advantage
of both the minimal invasiveness of needle
biopsy and the suitability of TA muscle for the
analysis of DM1 biomarkers, the small muscle
fragment obtained from a TA needle biopsy is
enough to perform an histopathological and
biomolecular characterization  of  skeletal
muscle in DM1 patients. This muscle charac-
terization will be used to monitor a DM1 clini-
cal trial by comparing the obtained results
before and after the therapeutic treatment. 
Materials and MethodsPatients and TA muscle biopsy
TA muscle biopsies were taken under sterile
conditions from 5 DM1 patients and from 5
healthy subjects and were used for this study
after receiving written informed consent from
the patients. The site is prepped with betadine.
Local anaesthesia is performed by 2% mepiva-
caine injection (7-8 cc) in the subcutaneous
tissue and intramuscular. A 1 cm transverse
skin incision is performed at the junction
between the proximal and middle third of the
anterior side of the leg, 2 cm laterally to the
tibial crest. Minimal blunt dissection is per-
formed to visualize the deep fascia, which is
then incised with a blade for 5 mm. An UCH
skeletal muscle needle with aspiration has
been used (Dixons Surgical Instruments Ltd.,
Wickford, UK). This needle is composed of two
concentric hollow. The outer (5 mm external
diameter) has a blunt point and a side window
and the inner, with a cutting edge at the end,
slides freely up and down acting as a guillo-
tine. There is a central plunger which is
removed during the sampling. A suction-sys-
tem is connected to the outer cylinder to obtain
samples.
The needle is inserted into the tibialis ante-
rior  muscle with its side window closed and
facing laterally. Once in the muscle, suction-
system is activated (200 mm Hg) and the inner
cylinder is withdrawn slightly, opening the
window. With the free hand, pressure is
applied on the outside of the thigh to cause the
muscle to bulge into the side window. The cen-
tral cylinder is then pushed home and a sample
obtained with the guillotine action of the cut-
ting edge.  The biopsy is performed perpendi-
cular to the longitudinal orientation of the
myofibers as opposed to open biopsies, and
repeated with a 45° angle to the skin, almost
parallel to the orientation of the myofibers,
similar to open biopsies. If necessary, more
muscle may be obtained by subsequent rein-
sertion of the needle through the same skin
incision. After withdrawal of the needle firm
pressure is applied to the thigh for 5 min to
prevent any hematoma. Since wound tension
is critical in lower limbs, the skin edges are
closed with 5-0 monofilament absorbable sub-
cutaneous stitches. Compressive dressing is
applied for 5 days. 
One sample of TA muscle of about 60 mg
was taken. One fragment of about 40 mg was
used for histological examination and one
fragment of about 20 mg was used for biomol-
ecular analysis. The diagnosis of DM1 was
based upon the clinical diagnostic criteria set
by the International Consortium for Myotonic
Dystrophy.32 DM1 genotyping has been per-
formed on genomic DNA extracted from
peripheral blood leukocytes as described.33
Clinical data on patients used in these study
are reported in Table 1. 
This study was authorized by the
Institutional Ethics Committee (ASL MI2,
Melegnano, MI, Italy) and was conducted
according to the principles expressed in the
Declaration of Helsinki, the institutional regu-
lation and Italian laws and guidelines.
Muscle histopathology andimmunohistochemistry
To identify the right orientation of the
fibers, a muscle sample of about 40 mg was
dissected under a stereomicroscope. Muscle
tissue was fresh-frozen in isopentane cooled
in liquid nitrogen. Histopathological analyses
were performed on serial sections (8 µm)
processed for routine histological or histo-
chemical stainings. A standard myofibrillar
ATPase staining protocol was used after prein-
cubation at pH 4.3, 4.6, and 10.4.35 The most
typical alterations, such as nuclear clump
fibers (i.e., aggregates of myonuclei with a
thin rim of cytoplasm), nuclear centralization
and fiber size variability, were analyzed on
serial muscle sections. Central nuclei and
nuclear clumps were classified as absent or
present. The evaluation of the area of the total
transverse section was made with Image J
(Scion Co., Frederick, MD, USA) on a single
digital image of the entire muscle cross-sec-
tional area obtained by tiling slightly overlap-
ping images of the transverse muscle section.
For immunohistochemistry, sections 6 µm
thick were air-dried and rehydrated in phos-
phate buffer pH 7.4 (PBS). Non-specific bind-
ing sites were blocked with normal goat serum
(NGS; Dako, Denmark) at a dilution 1:20 in
PBS containing 2% bovine serum albumin
(BSA; Sigma-Aldrich, St. Louis, MO, USA) for
20 min at room temperature (RT). Mouse
monoclonal primary antibodies against two
different myosin heavy chain (MHC) isotypes
were used at the following dilutions: MHCfast,
1:400 in PBS + 2% BSA; MHCslow, 1:400 in
PBS + 2% BSA (Sigma-Aldrich). Each antibody
was applied for 1 h at RT. After washing in PBS
3 times for 5 min, sections were incubated
with goat anti-mouse biotinylated secondary
antibody diluted 1:300 in PBS + 2% BSA for 1 h
at RT. After PBS washing (3x5 min), sections
were incubated with Vectastain Elite ABC kit
(Vector Laboratories, Burlingame, CA, USA)
for 30 min and then exposed to the 3,3’-
diaminobenzidine tetrahydrochloride (DAB;
Sigma-Aldrich) chromogen reaction solution
for 10 min. Nuclei were counterstained with
Mayer’s haematoxylin. Quantitative evaluation
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Table 1. Clinical data of DM1 patients.
Patients    Age at biopsy     Age at onset        CTG expansion           MRC           MIRS        Myotonia          Arrhythmia                   CPK
DM1-1                         33                               20                                   360                             129                     2                   Present                 Not present                 Normal values
DM1-2                         21                               15                                   460                           105.22                  2                   Present                     Present                           203 U/L
DM1-3                         27                               21                                   890                             105                     3                   Present                 Not present                 Normal values
DM1-4                         42                               18                                   190                             130                     2               Not present             Not present                 Normal values
DM1-5                         26                               13                                   360                           111.33                  3                   Present                 Not present                       531 U/L
MRC, Medical Research Council, scale for muscle strength; scale (0–5 grade) on 15 muscles at both side in the upper and lower limbs for a total of 150 maximum score; MIRS, muscle impairment rating
scale, stage of the disease for myotonic dystrophy type 1 (DM1) patients;39 CPK, creatine phosphokinase blood levels.
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of fiber diameter was made as described previ-
ously by Vihola et al.36 with Image J (Scion
Co.) on images taken with a light microscope
(160x, original magnification). The size of
muscle fibers was assessed by measuring the
smallest fiber diameter. 
All data were elaborated using Microcal
Origin (Microcal Software Inc., Northampton,
MA, USA). The metahistograms were normal-
ized to normal mean diameter for men and
women.Fluorescence in situ hybridizationcombined with MBNL1 immuno-fluorescence
The fluorescence in situ hybridization
(FISH) was performed on DM1 muscle frozen
sections using a (CAG)6-CA probe (IDT,
Coralville, IA, USA) as previously reported by
Cardani et al.37 Briefly, 6 µm thick transverse
cryostatic sections were air dried for 30 min
and fixed with 2% paraformaldehyde for 30
min at 4°C. The sections were then washed in
PBS and permeabilized for 5 min in 2% ace-
tone in PBS, prechilled at -20°C. After washing
in PBS, sections were incubated in 40% for-
mamide and 2x saline solution citrate (SSC)
for 10 min at RT, and hybridized for 2 h at
37°C, with 1 ng/L (CAG)6-CATexas red labeled
probe in 30% formamide, 2xSSC, 0.02% BSA,
67 ng/L yeast tRNA, 2 mM vanadyl ribonuclease
complex (all these reagents were from Sigma-
Aldrich, St. Louis, MO). The sections were
washed first in 40% formamide and 2xSSC at
45°C for 30 min, then in 1xSSC at 45°C for 15
min and another 1xSSC wash at RT. The FISH-
labeled sections were then processed for the
immunofluorescence detection of MBNL1, as
follows. The sections were pre-incubated for 20
min at RT with 5% NGS in PBS+2% BSA and
then incubated overnight at 4°C with the rab-
bit polyclonal antibody A2764 for MBNL1
(1:1000 in PBS+2% BSA). The sections were
washed in PBS and then incubated for 1 h at
RT with a goat anti-rabbit Alexa488-labeled
antibody (Molecular Probes, Life Technologies,
Milan, Italy), diluted 1:200 in PBS+2% BSA,
counterstained with DAPI (Sigma-Aldrich),
and mounted with Mowiol (Calbiochem, Milan,
Italy). cDNA synthesis
Frozen TA samples (20 mg) were practiced
for the extraction of total RNA using TRIzol
reagent (Life Technologies) and 20 ng of RNA
were reverse transcribed using the WT-
Ovation RNA Amplification System (NuGEN,
San Carlos, CA, USA) according to the manu-
facturer’s instructions. The resulting cDNAs
were used to perform both quantitative real
time-PCR (qRT-PCR) and classical PCR.
Quantitative RT-PCR 
The expression level of the DMPK gene was
measured by Quantitative RT-PCR (qRT-PCR)
using the Hs01094329_m1 Assay-on-demand
gene expression product, labeled with FAM
dye. GAPDH was chosen as the housekeeping,
internal control and its expression level was
measured using the Hs02758991_g1 Assay-on-
demand gene expression product, labeled with
FAM dye. Each PCR reaction was performed in
triplicate using the TaqMan Universal PCR
Master Mix - No AmpErase UNG (Applied
Biosystems, Life Technologies) and the
7900HT Fast Real Time PCR System (Applied
Biosystem, Life Technologies). Alternative splicing analysis
The RT-PCR splicing analysis for the INSR
(insulin receptor) was performed using
Platinum Taq Polymerase (Invitrogen,
Carlsbad, CA, USA) according to manufactur-
er’s protocol. Briefly, the reaction was conduct-
ed in a mix containing 150 ng of cDNA, Taq
MgCl2-free buffer, 2 mM MgCl2, 400 M dNTPs,
800 mM forward primer and 800 mM reverse
primer. After 2 min at 94°C, 35 cycles of ampli-
fication were performed, each consisting of 30
s at 94°C, 30 s at 60°C and 1 min at 72°C.The
RT-PCR splicing analysis for CAMK2G (calci-
um/calmodulin-dependent protein kinase II
gamma), CAMK2B (calcium/calmodulin-
dependent protein kinase II beta), CACNA1S
(dihydropyridine receptor), CLCN1 (skeletal
muscle chloride channel, voltage-sensitive 1),
NFIX (Nuclear Factor I/X), PDLIM3 (PDZ and
LIM domain 3) and LDB3 (LIM Domain
Binding 3) were performed using My Taq Red
Mix (Bioline), according to manufacturer’s
protocol. The PCR cycling conditions were: 1
min at 95°C followed by 35 cycles of 15 s at
95°C, 15 s at primer specific Tm, 10 s at 72°C.
The primers used for all PCR reactions were
listed in Table 2 with their respective tempera-
tures of melting (Tm). Total PCR products
were electrophoretically resolved on 2%
agarose gel for INSR, CAMK2G, CAMK2B,
CACNA1S, LDB3, NFIX and PDLIM3 genes and
3,5% agarose gel for CLCN1. 
Qualitative analysis of the amplified prod-
ucts was performed using EtBr-stained gels
(Sigma-Aldrich) scanned on a ChemiDoc
Universal Hood (Biorad). The quantitative
analysis was performed quantifying the inten-
sity of each band with ImageJ software densit-
ometry and calculating the fraction of abnor-
mally spliced (AS) isoform respect to the total
amount of isoforms (AS isoform/total). The
expression level of GAPDH was used as the
housekeeping, internal control. 
Results 
One aim of this work was to verify if a mus-
cle fragment of about 40 mg obtained from TA
needle biopsy of DM1 patients was adequate to
evaluate the histopathological alterations and
to analyze in situ biomolecular markers. The
mean area size of transverse muscle sections
obtained from 10 TA needle biopsies resulted
to be 1.75±0.74 mm2, about 13 fold smaller
than the area size of transverse sections
obtained from an open biopsy of biceps brachii
(data not shown). Nevertheless, routine stain-
ings performed on TA transverse sections per-
mit to evaluate the presence of the histological
alterations commonly observable in DM1
skeletal muscle such as nuclear clump fibers,
nuclear centralization and fiber size variability
(Figure 1). The results of histopathological
analysis of DM1 TA are reported in Table 3.
Moreover, the immunohistochemical staining
of MHC slow and fast myosin and the subse-
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Figure 1. Histological stainings of transverse sections of frozen tibialis anterior needle
biopsy of DM1 patients. A) Hematoxylin and eosin. B) Gomori trichrome. A high fiber
size variability with several atrophic (arrows) and hypertrophic (asterisks) fibers is evi-
dent. Scale bars: 50 µm
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quent analysis of type 1 and type 2 fiber diam-
eters allow to obtain metahistograms of fiber
diameter distribution (Figure 2) and to verify
the dystrophic changes. The results of the
analysis of immunostained sections were
reported in Table 3. 
To date, targeting the mutant RNA appears
to hold some of the greatest prospect for ther-
apeutic intervention in DM1. The reduction of
CUGexp RNA would be expected to release
sequestered MBNL1 protein and to improve its
splicing regulatory activity. Fluorescent in situ
hybridization (FISH) in combination with
MBNL1 immunofluorescence performed on
muscle sections is a useful method to reveal if
a reduction in the average number of foci of
CUGexp RNA and of MBNL1 before and after
the ASO treatment is evident. This reduction
can be evaluated on sections obtained from the
small muscle sample of TA needle biopsy since
the number of myonuclei that can be screened
(388±56 per mm2) is enough to obtain signifi-
cant results on changes in the number and
size of ribonuclear inclusions or MBNL1 foci.
All DM1 patients used in this study showed
ribonuclear inclusions colocalizing with
MBNL1 foci (Figure 3).
Consistent with MBNL1 activity restoration,
alternative splicing of MBNL1-dependent
exons should be examined in order to verify
the efficacy of the therapeutic treatment. To do
this it is necessary to use an efficient, sensi-
tive and reliable RNA-to-DNA conversion step
since the available muscle sample is limited.
NuGEN’s Ovation qPCR System is a highly effi-
cient system that provides a fast and simple
method for preparing amplified cDNA from a
very small input of total RNA. Moreover, 20%
more genes are detected using the amplified
cDNAs obtained with the Ovation qPCR System
than using those obtained with classical RT-
PCR techniques. This system amplifies the
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Figure 2. A,B) Fast myosin immunostaining of tibialis anterior  transverse sections of a
healthy subject (A) and of a DM1 patient (B); type 2 fibers (fast positive fibers) are
stained in brown; scale bars: 100 µm. C,D) Metahistograms obtained from the analysis
of muscle fiber diameters in a healthy subject (C) and in a DM1 patient (D). The results
are based on sections immunostained for MHC fast or slow myosin
Table 2. List of PCR primers used for alternative splicing analysis.  
Gene                                    Forward primer                                                           Reverse primer                                                    Tm (°C)
INSR                                                5’- CCAAAGACAGACTCTCAGAT-3’                                                  5’-AACATCGCCAAGGGACCTGC-3’                                               60
CAMK2G ex17                                5’-CAACGCTACAGATGGGATCA-3’                                                  5’-AAAGTCCCCATTGTTGATGG-3’                                                60
CAMK2G ex18                                5’-CTCCACAGAGAGCTGCAACA-3’                                                  5’-CAGGCTCAAAGGAAGTGAGG-3’                                              60
CAMK2B                                          5’- CAGGAGACTGTGGAGTGTCTG-3’                                             5‘-AGCGTCTTCATCCTCTATGGTGG-3’                                        62
CACNA1S                                        5’-GCTACTTTGGAGACCCCTGGAA-3’                                             5’-AGGAGGGTTCGCACTCCTTCTG-3’                                         60
CLCN1                                             5’-GGTTGTCCTGAAGGAATACCTCAC-3’                                        5’-TCCTCTCCAGTAGTTCCGAACAG-3’                                        60
LDB3 ex11                                      5’-GACTACCAGGAACGCTTCAACC-3’                                             5’-GACAGAAGGCCGGATGCTG-3’                                                62
LDB3 ex5                                         5’-GCGTCAACACAGACACCATGACC-3’                                          5’-TCATCTGGGCCAGGATGCGGAA-3’                                         62
NFIX                                                5’-GAGCCCTGTTGATGACGTGTTCTA-3’                                        5’-CTGCACAAACTCCTTCAGTGAGTC-3’                                     62
PDLIM3                                           5’-AGCCCATCCTTTCAAAATCAAC-3’                                               5’-AGAGCCATCGTCCACCATTC-3’                                                58
GAPDH                                            5’-AGCCTCCCGCTTCGCTCTCT-3’                                                  5’-GCCAGCATCGCCCCACTTGA-3’                                               60
Tm, melting temperature.
Table 3. Histopathological features of tibialis anterior needle biopsy in DM1 patients.
Patients                Central nuclei                   Nuclear clumps                AFast                      HFast                  ASlow                     HSlow 
DM1-1                                       Rare                                                Rare                                      +                                     ++                                -                                     ++
DM1-2                                     Absent                                            Absent                                     -                                        +                                 ±                                       -
DM1-3                                    Present                                           Absent                                    ±                                       +                                 +                                       -
DM1-4                                     Absent                                           Present                                  ++                                      -                                   -                                     ++
DM1-5                                       Rare                                              Absent                                     -                                      ++                               ±                                      +
AFast, fast fiber atrophy; HFast, fast fiber hypertrophy; ASlow, slow fiber atrophy; HSlow, slow fiber hypertrophy; -, absent; ±, modest; +, present; ++, prominent (grade based on fiber diameter
methahistograms).  
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entire transcriptome of 5-50 ng total RNA into
micrograms of cDNA across a wide range of
transcript abundance. 
In our study, the total RNA extracted from a
TA frozen sample of about 20 mg was around 8
µg. This quantity of RNA is sufficient to per-
form 400 RT-PCR using the Ovation qPCR
System starting from 20 ng of RNA for each
reaction. The total cDNA amount obtained was
around 2 mg. This quantity is enough to per-
form serial molecular analysis, such as qRT-
PCR and classical PCR, in order to evaluate the
expression levels of DMPK and the splicing
pattern of several genes involved in the multi-
systemic phenotype of DM1 patients respec-
tively. The analysis of the expression levels of
DMPK gene by qRT-PCR in muscle biopsy
showed that while in healthy patients the
expression levels of the gene are quite homo-
geneous, in DM1 patients an evident variabili-
ty in the amount of DMPK mRNA was observ-
able. Indeed in 3/5 DM1 patients the DMPK
expression is lower than that observed in
healthy subjects, while in two patients DMPK
expression is respectively 4 and 7 fold higher
than the media levels observed in healthy con-
trols and 7 and 11 fold higher than media levels
observed in the other DM1 patients (Figure
4A). Alternative splicing of several genes
involved in the multi-systemic phenotype of
DM1 was analyzed by RT-PCR. For each splice
event, the fraction of splice products that
included or skipped the alternative exon(s)
was compared for five healthy controls and five
DM1 subjects. We observed a splicing alter-
ation of CAMK2G exon 18, LDB3 exon 11 and
LDB3 exon 5 in 60% of DM1 patients and a
misregulation of INSR exon 11, CAMK2G exon
17, CAMK2B exon 13, CACNAS1 exon 29,
CLCN1 exon 7a isoforms, NFIX exon 7 and
PDLIM3 exon 5 in 80% of DM1 patients (Figure
4 B,C). 
Discussion
Clinical trials for a pharmacological treat-
ment need a road map to patient-focused bio-
marker measures. Therefore, the study of dis-
ease mechanisms, pathogenesis and manifes-
tations is required to select biomarker for the
conceptualization of treatment benefits.
Before treatment, it is also necessary to collect
data from registry of patients in order to under-
stand the natural history of muscle impair-
ment through longitudinal study. So it will be
easier to develop muscle impairment end-
points at clinical level, which are also very
helpful and necessary during clinical trial in
DM1. A phase I/II trial for the ASO ISIS-
DMPKrx is on-going in patients affected by
myotonic dystrophy type 1 in order to evaluate
the safety and tolerability of multiple doses of
this compound (www.clinicaltrials.gov). ISIS-
DMPKrx was designed to reduce the produc-
tion of toxic DMPK RNA in cells, including
muscle cells. Therapeutic application of this
strategy to DM1 patients is expected to cause a
rapid knockdown of CUGexp RNA in skeletal
muscle, correcting the physiological,
histopathological and transcriptomic features
of the disease. Published in vitro and in vivo
preclinical studies demonstrated that various
antisense oligomers targeting CUGexp repeats
induce the degradation of mutant DMPK tran-
scripts leading to a reduction of MBNL1
sequestration. Consequently, MBNL1 biologi-
cal function is restored and the splicing alter-
ation of several genes is corrected including
CLCN1 alternative splicing leading to an
improvement of myopathic changes.12-20
In view of a clinical trial on large scale, it
appears evident the need to improve specific
tools and to define biomolecular markers that
can be used for monitoring the success of the
therapy. In particular, it is necessary to vali-
date tools characterized by feasibility and the
test-retest reliability. The needle biopsy is a
minimally invasive procedure that presents a
low complication rate, causes a short scar and,
therefore, it can be repeated on the same
patient and on the same muscle over the time.
These features make needle biopsy a good can-
didate as a tool to follow a clinical trial on DM1
patients. However, one limitation of this proce-
dure is that the tissue samples obtained are
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Figure 4. A) DMPK gene expression measured by qRT-PCR; GAPDH was chosen as the
housekeeping, internal control; each PCR reaction was performed in triplicate. B) RT-
PCR splicing analysis of the indicated genes in 5 healthy subjects and in 5 DM1 patients;
arrows indicated the different alternative splicing products: the products that include the
specific exon (Ex) and those that exclude the specific exon (D); the loading control was
based on the expression levels of the GAPDH. C) Analysis of the percentage of altered
isoform expression of the indicated genes. Histograms represent mean ± SD.
Figure 3. FISH in combination with MBNL1-immunofluorescence reveals the presence
of foci (arrows) of toxic RNA (red spots in panel A) and of MBNL1 (green spots in panel
B) co-localizing in nuclei (visualized by the DAPI blue fluorescence) of TA muscle fibers.
Scale bars: 10 µm.
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very small. The main effort of this work was
therefore to set the conditions in order to suc-
ceed in performing histopatological examina-
tion and biomolecular analysis on small mus-
cle fragments obtained with needle biopsy. All
the analysis were performed on TA muscle
since it appears to be the best muscle to test
therapeutic interventions in DM1 patients.28 
The analysis performed on TA muscle sec-
tion obtained from needle biopsy indicates
that, despite the small fragment dimensions,
the cross-section area obtained was enough to
evaluate structural changes in muscle fibers,
central nuclei frequency, muscle fiber diame-
ter  and presence of CUGexp RNA and MBNL1
foci. These parameters should be taken in con-
sideration to verify if the therapeutic treat-
ment can protect against structural changes
(mainly a prevention of fiber atrophy) and can
decrease toxic RNA and MBNL1 accumulation.
The use of specific reverse transcription and
amplification systems allowed us to obtain a
huge amount of cDNA starting from small
amount of RNA. This permitted us to analyze
DMPK expression levels in our TA muscle sam-
ples. As previously reported, our results show
an inter-individual variability in DMPK expres-
sion in DM1.38 DM1 is associated with the mis-
regulation of alternative splicing of many
genes that can explain the multisystemic phe-
notype of the disease. For this reason, splicing
events in skeletal muscle are  useful biomark-
ers of DM1 therapeutic response. The amount
of cDNA obtained also permit us to analyse the
splicing alteration of a large number of genes
such as INSR and CLCN1 that are involved in
insulin resistance and myotonia respectively
and CACNA1S whose misplacing may con-
tribute to muscle degeneration. The obtained
data confirmed that the percentage of splicing
misregulation observed in our DM1 patients is
similar to the percentage reported by
Nakamori et al.28 However, it is reasonable to
consider that in clinical trial only splice events
of genes that correlate with skeletal muscle
symptoms will be examined, on the assump-
tion that the correction of these defects may
lead to functional improvement.39
The main limitation of this study is that it
does not extend our knowledge on DM1 patho-
mechanism beyond what is already known.
Some data presented in this study were
already discussed by Nakamory et al.28 who
studied more muscle samples and more splic-
ing events. However, the aim of our study was
to asses if histological and biomolecular bio-
markers might be evaluated on a small frag-
ment of TA muscle to obtain the data necessary
to evaluate the effects, positive as well as neg-
ative, of therapeutic treatment in DM1
patients. Indeed, by using the minimally inva-
sive needle biopsies technique for sampling
the small fragment of muscle, the procedure
can be performed before and after the treat-
ment on the same patient.
In conclusion, our analysis demonstrates that
using a minimally invasive procedure as needle
biopsy it is possible to obtain small TA fragments
which are an adequate amount of muscle tissue
to perform all the histopathological and biomol-
ecular analysis useful to monitor the success of
a clinical trial on DM1 patients.
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